Index

Note: Page numbers of article titles are in **bold face** type.

ACHONDROPLASIA, 15–18
  pathophysiology and treatment, 17–18
  rheumatic manifestations, 16–17
Acromegaly, 95–99
Amyloid arthropathy, synovial fluid in, 155–156
Amyloid disease—
  literature on, 150–151
  rheumatological aspects of, **149–159**
Amyloid in the synovial membrane, microscopic anatomy of, 156–157
Amyloidosis—
  articular manifestations of, 153–155
  associated rheumatological findings, 155
  in familial Mediterranean fever, 198–199, 207
Arthritis—
  body habitus and, 49–50
  of hyperparathyroidism, haemochromatosis and Wilson's disease, **109–115**
  septic, 42
Arthropathy, chronic haemophilic, 72–81
  clinical features of, 79
  experimental evidence, 72–73
  human histopathology, 73–74
  incidence, 79
  management, 80–81
Arthropathy of secondary haemochromatosis, 49
Articular hypermobility syndrome, 12–13
  physiopathology and treatment, 13
  rheumatic manifestations, 13
Aspiration—
  in haemarthrosis, 68–69
  in intramuscular bleeding, 86

BLEEDING into muscle, 81–86
  aetiology, 82
  clinical features, 82–85
  contractures, 84–85
  incidence, 81
  pathology, 82
  treatment, 85–86
Bone disease, arthritis secondary to, 109–110
Bone infarctions, 43–44
Bone trabecular changes associated with expansion of the marrow, 38–39

CHONDROCALCINOSIS and pyrophosphate arthropathy, 112–115
Christmas disease, 58
Cirrhosis, primary biliary, 183
Clotting factor replacement in haemarthrosis, 66–67
Colchicine, in treatment of familiar Mediterranean fever, 207
Connective tissue, rheumatic manifestations of heritable disorders of, **3–34**
Cyst formation in systemic lupus erythematosus, 143, 145

Dermato-arthritis, familial histiocytic, 182
Diabetes mellitus, 102–105
Distension/swelling in haemarthrosis, 64
Dupuytren's contracture, 33–34

EHLERS–Danlos syndrome, 3–9
  physiopathology and treatment, 8–9
  variants of, 6–8
Endocrinopathies, rheumatological complications of some, **95–106**
Epiphyseal dysplasias, 24–32
  pathophysiology and treatment, 32
  rheumatological manifestations, 26–32
Erythema, erysipelas-like, 197

Fabry's disease, 175–176
Factor IX deficiency, 58
Familial Mediterranean fever—
  articular manifestations, **195–209**
  histological findings, 202
Farber's disease, 182
Fibrodysplasia ossificans progressiva, 18

GAUCHER's disease, 174–175
Glycolipidosis, 175–176
Gout, 110–112
  hyperuricaemia and, 40
  lipid metabolism and, 163–164
Granulomatosis, lipophagic intestinal, 183–184

HAEMARTHROSIS, 48
Haemarthrosis, acute—
clinical features, 63–65
diagnosis, 66
examination, 65
history, 65
pain, 63–64
pathology, 61–63
radiology, 65
treatment, 66–72
Haemochromatosis, 115–120
Haemophilia—
antibodies to Factor VIII, 58
bleeding manifestations, 54–55
diagnosis, 55
incidence, 53
inheritance, 53–54
management of bleeding, 55–56
principles of replacement therapy, 57–58
replacement therapy materials, 56–57
Haemophilias—
reconstructive surgery, 86–90
results of treatment, 90–91
rheumatological manifestations, **53–91**
Haemotoxylin bodies, 145
Hand–foot syndrome, 40–41
Histiocytosis, sea-blue, 176–177
Histiocytosis-X, 177–179
Hook formation in systemic lupus erythematosus, 137, 140
Hyperlipoproteinuria, 164–165
Type 2, 166–170, 171
Type 4, 170, 172
Hyperparathyroidism, haemochromatosis and Wilson's disease, the arthritis of, **109–115**
Hyperthyroidism, 102
Hypolipoproteinaemia, 172
Hypothyroidism, 99–101

IMMOBILISATION—
in haemarthrosis, 67–68
of bleeding muscle, 85–86
Intestinal malabsorption, some disorders of, 184

JACCOUD'S syndrome, **125–147**
Joint effusions, 46–48
Joint lesions—
in familial Mediterranean fever, 201
pathological aspects of acute in systemic lupus erythematosus, 132

LIPID metabolism—
disorders of the locomotor system giving rise to abnormalities of, 163–164
disorders of, giving rise to musculoskeletal symptoms, 164–182
Lipoidoses and musculoskeletal complications, 174
Locomotor system, disorders of associated with abnormalities of lipid metabolism and the lipoidoses, **163–185**

MARFAN'S syndrome, 9–11
physiopathology, diagnosis and treatment, 11
rheumatic manifestations, 10–11
Mediterranean fever, familial—
articular manifestations, **195–207**
clinical manifestations, 196–199
diagnosis, 199–200
ethnic origin and inheritance, 195–196
treatment, 205–207
Mucopolysaccharidoses, the, 18–24
pathophysiology and treatment, 24
rheumatological manifestations, 19, 22–23
Musculoskeletal and lipid abnormalities, systemic disorders associated with, 183–185
Myeloma, multiple—
age and sex distribution, 152
data relevant to diagnosis of, 151–152

NECROSIS, aseptic, 44–46

OBESITY and osteoarthrosis, 172–173
Osteomyelitis, 42

PAGET'S disease, 32–33
pathophysiology and treatment, 33
Pancreatic disease, 102–106
Pancreatic diseases and musculoskeletal disorders, 184–185
Pancreatitis, 105–106
Peritoneal attack, in familial Mediterranean fever, 197
Pleural attack, in familial Mediterranean fever, 197
Pseudoxanthoma elasticum, 13–15
pathophysiology and treatment, 14–15
rheumatic manifestations, 14
Pyrophosphate arthropathy, chondrocalcinosis and, 112–115

RADIOGRAPHIC changes, in familial Mediterranean fever, 202–203
Radiological changes, in Jaccoud's syndrome, 130–132
Rehabilitation—
after intramuscular bleeding, 86
in haemarthrosis, 69–70
Reticulohistiocytosis, multicentric, 179–182
Rheumatic manifestations of heritable disorders of connective tissue, **3–34**
Rheumatoid arthritis, and lipid metabolism, 164
Rheumatological aspects of amyloid disease, **149–159**

Rheumatological complications of some endocrinopathies, **95–106**

SICKLE-CELL disease and other hereditary haemoglobinopathies, rheumatological manifestations of, **37–50**
Sickle-cell trait, 50
Spondylo-epiphyseal dysplasia, 25–26
Synovial fluid findings in familial Mediterranean fever, 202
Systemic lupus erythematosus—
  Jaccoud's syndrome and, 125–147
  lipid metabolism and, 164
  pathological aspects of acute joint lesions, 132
  pathological changes and chronic stage, 133–146
Synovitis, clinical aspects of early acute, 126–130

THYROID disease, 99–102

VON WILLEBRAND'S disease, 58–59

WHIPPLE'S disease, 183–184
Wilson's disease, 120–121

Index

Note: Page numbers of article titles are in **bold face** type.

ACETYLSALICYLATE, 250
  distribution and metabolism of, 252–253
Acetylsalicylate and salicylate kinetics in rheumatoid arthritis, 253–254
ACTH—
  and glucocorticoids in rheumatoid arthritis, the importance of, **335–360**
  release of pituitary, 336–337
  vs. glucocorticoids, 351
ACTH preparations, 346–348
ACTH, synthetic, 346–351
  complications of, 351
  optimal dose for management of rheumatoid arthritis, 348
  potency, 348–349
  regimen of administration, 349–350
Adrenal cortex, physiology of, 335–338
Alclofenac, 296–297
Amyloidosis, 437–438
Anaemia, 430–431
  and salicylates, 256
Analgesia and anti-inflammation, 357–359
Analgesia and anti-inflammatory mechanisms, 245–261
Analgesic anti-inflammatory agents, 449–450
Analgesic nephropathy, 256
Ankylosing spondylitis, phenylbutazone, indomethacin and, 274–275
Antibody-mediated component, mode of action of glucocorticoids against, 355–356
Antibody production, effect of glucocorticoids on, 355–356
Anti-inflammatory drugs, patients, physicians and, 230
Anti-rheumatic drugs, more recent non-steroidal, **285–302**
Arthrodesis, 389, 405, 409, 420–421
Arthroplasty, 387, 389–395, 410
  excisional, 410
  interpositional, 403–404, 406, 408
  replacement, 402–403, 405, 410–418, 419–420
Aspirin, 449
  clinical applications, 294
  gastric tolerance and mucosal bleeding, 249–250
  haemorrhagic tendency of, 257
Aspirin or paracetamol 'count', 230
Azathioprine, 461–462
  side effects of, 469

BENORYLATE, 297
Blood dyscrasia, D-penicillamine and, 330
Blood flow and permeability, 231–232

CARDIOVASCULAR system, effects of aspirin on, 257
Carpometacarpal joint, 421
Cell-mediated component, mode of action of glucocorticoids against, 353–355
Cerebro-hypothalamic-pituitary-adrenal function in patients with rheumatoid arthritis, 337–338
Chelating action of D-penicillamine, 321–322
Chloroquine, 451
Cyclophosphamide, 462
  side effects of, 467–469

DEFORMITY, prevention of in juvenile chronic polyarthritis, 444
Disability, evaluation of functional, 229–230
Disease activity—
  new research findings and, 239
  radiological assessment of, 233–234
Disease improvement—
  and drug treatment, 237–239
  and pathogenic mechanism, 234–239
  laboratory assessments of, 234
  non-specific laboratory changes and, 236–237

ELBOW, surgery of in rheumatoid arthritis, 402–404
Exercise, rest and, 218–221
Exercises, 221–222

Febrile reactions, early, D-penicillamine and, 330
Felty's syndrome, 432
Fenoprofen, 296
Fibrosis, diffuse interstitial, 435
Foot, surgery of in rheumatoid arthritis, 395–399

GASTROINTESTINAL disturbances, D-penicillamine and, 329
Glucocorticoid treatment, intra-articular, 352–357
Glucocorticoids—
  dosage, 342–343
  importance of ACTH and, in rheumatoid arthritis, **335–360**
  present clinical status, 342–343
  synthetic, 343–346
    complications, 346
    dose and regimen of administration, 345–346
  vs. ACTH, 351
Gold therapy, **307–315**, 450–451
  administration and dosage, 313–315
  efficacy, 307–308
  haematological toxicity of, 312–313
  kinetics, distribution and retention, 306–309
  mechanism of action, 309–310
  mucocutaneous side effects, 311
  nephropathy and, 311–312
  ocular side effects, 313
  pharmacology, 308–310
  terminology, 308
  toxicity from, 310–313
  unusual toxic manifestations of, 313
Gout, phenylbutazone, indomethacin and, 275–276
Grip strength, measurement of, 227–228

HAND, surgery of the, in rheumatoid arthritis, **401–426**, 409–421
Harrison–Strut procedure, 422
Heat and cold, 222–223
Hepatotoxicity, 256
Hip arthroplasty, place of in management of rheumatoid arthritis, 380
Hip, surgery of the—
  complications of, 376–379
  in rheumatoid arthritis, **367–380**
  medical aspects of, 375–376
  operative procedures, 372–375
  selection of patients for, 369–372
Hip, surgical pathology of the, 367–368
Home, aids in the, 223
Home or hospital?, 223
Hypercortisonism, 340–341
Hypersensitivity, aspirin, 257

IBUPROFEN, 295, 450
Immunosuppression, and D-penicillamine, 322–323
Immunosuppressive agents, general problems in administration of, 470–472
Immunosuppressive agents currently available, 460–463
Immunosuppressive drugs: mechanism of action, toxicity and clinical effects, **459–476**
Immunosuppressive therapy, 454
Indomethacin, 449–450
  absorption, 271–272
  intolerance, sensitivity reactions and toxicity, 278–279
  phenylbutazone and, **267–280**
Inflammation, effects of phenylbutazone and indomethacin on local mediators of, 269
Interphalangeal joints, proximal, 419–421
Intra-articular glucocorticoid treatment, 352–357
  mode of action, 352–357

JOINT pains, D-penicillamine and, 330
Joint size, measurement of, 228
Joint stiffness, assessment of, 229
Joint tenderness, measurement of, 227

KETOPROFEN, 296
Knee and foot, surgery of in rheumatoid arthritis, **383–399**

LEUCOCYTES, effect of glucocorticoids on PMN, 356–357
Lysosomal membranes, stabilising effect of non-steroid anti-rheumatic drugs, 289–290
Lysosomes and lysosomal enzymes, effects of phenylbutazone and indomethacin on, 269

MACROPHAGES, effect of glucocorticoids on, 355
Management of patient, general measures of, and approach to, **217–224**
Metacarpophalangeal joints, 409–418, 422–424
Methotrexate, 462–463
  side effects of, 469–470
Myocardial and endocardial lesions, 436–437

NAPROSYN, 295–296
Neuropathy, sensory, 430
Non-steroidal anti-rheumatic drugs—
  animal models for screening, 285–286
  clinical application, 293–302
  combinations of, 300–301
  effect of on biochemical systems, 286–293
  mode of action, 285–293

OSTEOARTHRITIS, phenylbutazone, indomethacin and, 276
Osteotomy, 388

PAIN, assessment of, 226–227
Pain control, 221

Patient, approach to the, and general measures of management, **217–224**
Patient education, 217–218
Patient selection—
  for salicylates, 255
  for surgery of the hip, 369–372
Patients, and compliance with prescribed drugs, 255
Penicillamine, 451
D-penicillamine—
  administration and dosage, 326–327
  as anti-viral agent, 322
  clinical benefits, 324–325
  extra-articular manifestations, 325–326
  failure of patients to respond to, 325
  history, 319–320
  in rheumatoid arthritis, **319–331**
  indications for, 327
  lathyrogenic action of, 323–324
  metabolism, 320
  possible mode of action, 320–324
  side effects, 327–330
Peptides, and non-steroidal anti-rheumatic drugs, 287
Pericarditis, 435–436
Permeability, blood flow and, 231–232
Phenylbutazone—
  absorption, 270–271
  analgesic effect, 267–268
  anti-inflammatory effect, 268
  antipyretic effect, 268
  effects on electrolytes and uric acid, 268
  pharmacological actions of, 267–269
Phenylbutazone and indomethacin, **267–280**
  contra-indications for, 280
  drug interactions with, 279–280
  intolerance, sensitivity reactions and toxicity, 277–278
  mode of action, 269–270
  systemic and local effects, 269–270
  use in specific indications, 273–277
  uses in clinical rheumatology, 272–273
Phosphorylation, non-steroidal anti-rheumatic drugs as uncoupling agents in oxidation, 287–289
Physical measures, in management of patient, 221–224
Physiotherapy, in juvenile chronic polyarthritis, 446–448
Platelet aggregation, effect of phenylbutazone and indomethacin on, 270
Polyarthritis, juvenile chronic—
  drug therapy, 448–454
  treatment of, **443–456**
Prostaglandin synthesis, inhibiting effects of non-steroidal anti-rheumatic drugs, 290–293
Proteins, effect of phenylbutazone and indomethacin on stabilisation of, 269–270
Pulmonary rheumatoid nodules, 435
Pyridoxine antagonism of D-penicillamine, 322

RADIOACTIVE technetium scans, 232–233
Radiological assessment of disease activity, 233–234
Rashes, D-penicillamine and, 329
Renal disease, D-penicillamine and, 328–329
Rest and exercise, 218–221
Rheumatic conditions, various, and phenylbutazone and indomethacin, 276–277
Rheumatism Unit, 223–224
Rheumatoid arthritis—
  acetylsalicylate and salicylate kinetics in, 253–254
  anti-inflammatory effect in, 246–247
  cerebro-hypothalamic-pituitary-adrenal function in patients with, 337–338
  detection of change in disease activity in patients with, **225–239**
  importance of ACTH and glucocorticoids in, **335–360**
  pathology, 231
  D-penicillamine in, **319–331**
  phenylbutazone and indomethacin and, 273–274
  place of hip arthroplasty in management of, 380
  pleural reactions, 434–435
  results of immunosuppressive therapy in, 472–475
  reversibility of, 338–340
  salicylates in, **245–261**
  surgery of the hand in, 401–426
  surgery of the hip in, **367–380**
  surgery of the knee and foot in, **383–399**
  treatment of complications of, **429–440**
Rheumatoid arthritis, juvenile, D-penicillamine and, 325
Rheumatoid nodules, pulmonary, 435
Rheumatoid vasculitis, 429–430

SALICYLATE plasma, concentration of and metabolism of, 252–253
Salicylates—
  absorption, 247–248
  adverse reactions and other problems, 255–257
  in rheumatoid arthritis, **245–261**
  interactions between other drugs, 257
  possible benefits not evident from trials, 247
  prescribing and dose recommendations, 250–252
Salicylism, 255–256
Scleritis and episcleritis, 434
Sepsis, 440
Sjögren's syndrome, 438–440

Splenectomy, results of in Felty's syndrome, 432–433
Splintage, 221
Steroid therapy, in polyarthritis, 451–453
Steroids, gold and other therapies in Felty's syndrome, 433
Sulphydryl reducing action of D-penicillamine, 321
Synovectomy, 384–385, 388, 402, 404, 409

TASTE, loss of, and D-penicillamine, 329
Temperature recording, 231
Tendons in rheumatoid arthritis, 422–424
Thumb, surgery of in rheumatoid arthritis, 421–425
Tissue—
  effect of phenylbutazone and indomethacin on metabolism of inflamed, 270
  effect of phenylbutazone and indomethacin on synthesis of connective, 270
Trapezium replacement, 421–422

ULCERATION, oral, D-penicillamine and, 330

VASCULITIS, rheumatoid, 429–430

WRIST, surgery of the, in rheumatoid arthritis, 404–409

Index

Note: Page numbers of article titles are in **bold face** type.

ADRENOCORTICOSTEROIDS, and systemic lupus erythematosus (SLE), 633–634
ANA in immune complex formation, the role of, 555–557
Animal models and type C viruses, 507–510
Anticonvulsants, and SLE, 634
Anti-DNA antibodies, 546–548
  some methods for the detection of, 551–552
Antimalarials and SLE, 634
Antinuclear antibodies induced by drugs, specificity of, 576
Antinucleic acid antibodies in SLE—clinical and pathological significance, **545–557**
Autoimmunity and lymphoid malignancy—
  in canine lupus, 491–492
  in NZB mice, 485–487

BLOOD coagulation, abnormalities of, 583–590

CELL-MEDIATED immune responses, mechanisms of, 497–499
Cell-mediated immunity in SLE, **497–502**
Central nervous system, complement in the, 535
Central nervous system disease, efficacy of cytotoxic agents against, 673–674
Complement—
  in lupus, **519–538**
  in renal lesions, 531–533
  in the central nervous system, 535
  isolated inherited defects of, 524–528
  pleuro-pericardial, 534
  synovial fluid, 535
Complement abnormalities, acquired sera, 528
Complement components, measurement of, 523–524
Complement levels, miscellaneous, 536
Complement levels, serum, and renal disease, 528–531
Complement metabolism, 536–537
Complement sequence, relation of to the mediators and inflammation, 523
Complement system—
  immunobiology, 522–523
  sequence, 519–522
Connective tissue disease, mixed—overlap syndromes, **561–570**
Counter-immunoelectrophoresis, 551–552
Cytotoxic agents—
  efficacy against central nervous system diseases, 673–674
  efficacy against renal disease, 669–673
  efficacy against systemic disease, 668–669
  in the management of SLE, **665–675**
  reason for use of, 665–667
  treatment of SLE with, 667–668
  unwanted effects, 674–675
Cytotoxic drugs in lupus nephritis, 656–658

DERMAL-EPIDERMAL junction, pathophysiology of, 607–609
Diffuse proliferative lupus nephritis, 643–645
Discoid lupus, 605–606
  lesional skin, 605
  non-lesional skin, 605–606
DNA, as the immunogen, 553
DNA antibodies—
  aetiology of, 552–554
  and disease activity, 550–551
  clinical significance of, 548–550
  experimental models, 552–553
DNA-binding test, 547–548
DNAse inhibitors, 553
Drug-induced lupus, management of, 579
Drug-induced SLE and related syndromes, **573–579**

FAMILY planning in SLE, 613–614
Fibrinogen–fibrin conversion, abnormalities of, 590
Focal proliferative lupus nephritis, 642–643

GLOMERULAR sclerosis in lupus nephritis, 655

HAEMOSTATIC disorders in SLE, **583–594**

IMMUNOBIOLOGY of complement system, 522–523
Immunofluorescence using Crithidia, 552
Immunological factors, circulating, in lupus nephritis, 658–659

Immunological function in NZB mice, 487–491
Immunosuppressive drugs and SLE, 634

LUPUS—
autoimmunity and lymphoid malignancy in canine, 491–492
experimental drug-induced, and antinuclear antibodies, 579
management of drug-induced, 579
Lupus-activating drugs, classification of, 573–576
Lupus-activating potency of various drugs, 576–577
Lupus anticoagulant, the, 584
biochemical properties of the, 587
decreased prothrombin concentrations, 588
should it be treated?, 588
Lupus band test, the, **597–609**
diseases other than SLE and discoid lupus, 606–607
effect of on coagulation tests, 584–586
mechanisms of action, 586–587
Lupus erythematosus, animal models for systemic, **485–495**
Lupus nephritis, **639–660**
circulating immunological factors and, 658–659
classification of, 640–641
diffuse proliferative, 643–645
focal proliferative, 642–643
glomerular sclerosis in, 655
membranous, 645, 652
mesangial, 652–654
microtubular particles in, 656
natural history of, 641–654
therapy with cytotoxic drugs, 656–658
Lupus neurological disease, disturbances of mental function in, 623–624
Lupus predisposition, 578–579

MEMBRANOUS lupus nephritis, 645, 652
Mental function, disturbances of, 623–624
Mesangial lupus nephritis, 652–654
Metabolism, complement, 536–537
Mixed connective tissue disease, **563–570**
clinical characteristics, 563–565
laboratory characteristics, 565–568
summary and conclusions, 569–570
treatment, 568–569

NZB MICE—
autoimmunity and lymphoid malignancy in, 485–487
immunologic function in, 487–491
Neuropsychiatric abnormalities in SLE, **621–635**
clinical manifestations, 621–623

OVERLAP syndromes—mixed connective tissue disease, **561–570**

PARALYSIS, limb, and SLE, 625–626
Platelet function, abnormal, 593
Pleuro-pericardial complement, 534
Polyarteritis nodosa and subacute sclerosing panencephalitis, 510
Pregnancy—
effect of on SLE, 614–616
SLE and, **613–619**
patient management during, 617–618

RENAL disease—
cytotoxic agents and, 669–673
serum complement levels and, 528–531
Renal lesions, complement in, 531–533
RNA antibodies, 554–555

SERUM complement levels—
and non-renal features, 533–534
and renal disease, 528–531
Synovial fluid complement, 535
Systemic disease, cytotoxic agents and, 668–669
Systemic lupus erythematosus (SLE)—
and pregnancy, **613–619**
animal models for, **485–495**
antinucleic acid antibodies in—clinical and pathological significance, **545–557**
breast feeding and, 618
cell-mediated immunity in, **497–502**
clinical correlations with lupus band test, 602–605
complement as a guide to diagnosis and therapy, 537–538
complement in, **519–538**
cytotoxic agents in the management of, **665–675**
defective cell-mediated immunity, 499–500
diagnosis, 629–630
disease course and prognosis, 630–633
drug-induced, and related syndromes, 573–579
drug-induced, clinical manifestations of, 577
effect of cessation of the drug on the clinical course of, 578
effect of on pregnancy and fetus, 616–617
epidemiological studies, 511
evidence for virus infection in, 511–516
Factor VIII inhibitors, 588–589
Factor IX inhibitors, 589
Factor XI and XII inhibitors, 589
haemostatic disorders in, **583–594**
immunoglobulin class and complement components, 602
immunological studies: virus antibodies, 512–513

Systemic lupus erythematosus (SLE)—*continued*
miscellaneous studies: CMI to viruses and interferon, 514
morphological studies: virus-like inclusions, 511–512
movement disorders in, 626
murine and canine, 509–510
neuropathies in, 625
neuropsychiatric abnormalities in, **621–635**
non-lesional skin, 601–602
pathophysiology of brain in, 626–629
patient management during pregnancy, 617–618
platelet abnormalities in, 590–593
renal vasculitis in, 656
role of viruses in, **505–517**
seizures in, 624–625
skin lesions, 597–601
theoretical implications of defective cell-mediated immune responses, 501–502
therapy, 633–634
use of lupus-inducing drugs in patients with spontaneous, 579
viral hypothesis, 505–507
virologic studies, 514–516

T-CELL function, 553–554
Thrombocytopenia, 590–593
treatment, 592–593

UV LIGHT irradiated DNA, 553

VIRAL antigen detection, 516
Virus isolation, 514, 516
Viruses, animal models and type C, 507–510
Viruses in SLE, the role of, **505–517**
Von Willebrand's disease, acquired, 590